Entropy Neurodynamics Limited (ENP) - Total Liabilities
Based on the latest financial reports, Entropy Neurodynamics Limited (ENP) has total liabilities worth AU$1.13 Million AUD (≈ $797.70K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Entropy Neurodynamics Limited - Total Liabilities Trend (2018–2025)
This chart illustrates how Entropy Neurodynamics Limited's total liabilities have evolved over time, based on quarterly financial data. See Entropy Neurodynamics Limited working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Entropy Neurodynamics Limited Competitors by Total Liabilities
The table below lists competitors of Entropy Neurodynamics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Prime Oil Chemical Service Corp
TW:2904
|
Taiwan | NT$543.43 Million |
|
Univastu India Limited
NSE:UNIVASTU
|
India | Rs2.18 Billion |
|
Global Menkul Degerler AS
IS:GLBMD
|
Turkey | TL2.16 Billion |
|
Thirdeye Systems Ltd
TA:THES
|
Israel | ILA31.28 Million |
|
Century Lithium Corp.
V:LCE
|
Canada | CA$184.90K |
|
Drone Volt SA
PA:ALDRV
|
France | €8.88 Million |
|
Gunpoint Exploration Ltd
V:GUN
|
Canada | CA$335.00K |
|
Kunming Longjin Pharmaceutical Co Ltd
SHE:002750
|
China | CN¥69.96 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Entropy Neurodynamics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Entropy Neurodynamics Limited market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 5.70 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Entropy Neurodynamics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Entropy Neurodynamics Limited (2018–2025)
The table below shows the annual total liabilities of Entropy Neurodynamics Limited from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$699.17K ≈ $494.71K |
-61.85% |
| 2024-06-30 | AU$1.83 Million ≈ $1.30 Million |
+4.47% |
| 2023-06-30 | AU$1.75 Million ≈ $1.24 Million |
-63.50% |
| 2022-06-30 | AU$4.81 Million ≈ $3.40 Million |
+85.57% |
| 2021-06-30 | AU$2.59 Million ≈ $1.83 Million |
+69.81% |
| 2020-06-30 | AU$1.53 Million ≈ $1.08 Million |
+442.75% |
| 2019-06-30 | AU$281.00K ≈ $198.83K |
-10.94% |
| 2018-06-30 | AU$315.53K ≈ $223.26K |
-- |
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more